Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 541 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR From smart knives to virtual reality tumours: five innovations in understanding... August 29, 2022 Rookie Cop Saves Infant From Choking October 24, 2021 FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease August 17, 2021 Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once... September 26, 2024 Load more HOT NEWS Breast Cancer Survivor Comes First Woman In The World To Give... Targeting Inflammation Emerges as a Strategy for Treating Cancer 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... ΚΑΡΚΙΝΟΣ ΤΟΥ ΝΕΦΡΟΥ
